Camurus Nomination Committee for 2027 AGM Appointed
Camurus has announced the composition of its Nomination Committee for the 2027 Annual General Meeting (AGM). The committee comprises four members representing approximately 38 percent of the company's shares and votes.
Lund, Sweden – September 11, 2026 – Pharmaceutical company Camurus has appointed the members of the Nomination Committee for its 2027 Annual General Meeting (AGM). The committee includes Per Sandberg, appointed by Sandberg Development AB; Arne Lööw, appointed by Fjärde AP-fonden; Anna Henricsson, appointed by Handelsbanken Fonder; and Camurus' Board Chairman, Per Olof Wallström.
Collectively, these members represent approximately 38 percent of the total number of shares and votes in Camurus, based on the latest available shareholder information. The Nomination Committee's primary role is to prepare proposals for the AGM, including recommendations for the composition of the Board of Directors and the Chairman of the Board.
The formation of this committee is part of Camurus' established corporate governance procedures. The committee's proposals are expected to be presented in due course. This structure allows significant shareholders to contribute to the selection of the company's leadership.
Camurus is focused on the development and commercialization of long-acting drug delivery systems. The company's therapeutic areas include pain management and reproductive health.